Resumen
Alzheimer's disease (AD) is the most common form of dementia. AD brain pathology starts decades before the onset of clinical symptoms. One early pathological hallmark is blood-brain barrier dysfunction characterized by barrier leakage and associated with cognitive decline. In this review, we summarize the existing literature on the extent and clinical relevance of barrier leakage in AD. First, we focus on AD animal models and their susceptibility to barrier leakage based on age and genetic background. Second, we re-examine barrier dysfunction in clinical and postmortem studies, summarize changes that lead to barrier leakage in patients and highlight the clinical relevance of barrier leakage in AD. Third, we summarize signaling mechanisms that link barrier leakage to neurodegeneration and cognitive decline in AD. Finally, we discuss clinical relevance and potential therapeutic strategies and provide future perspectives on investigating barrier leakage in AD. Identifying mechanistic steps underlying barrier leakage has the potential to unravel new targets that can be used to develop novel therapeutic strategies to repair barrier leakage and slow cognitive decline in AD and AD-related dementias.
| Idioma original | English |
|---|---|
| Número de artículo | 108119 |
| Publicación | Pharmacology and Therapeutics |
| Volumen | 234 |
| DOI | |
| Estado | Published - jun 2022 |
Nota bibliográfica
Publisher Copyright:© 2022 The Author(s)
Financiación
This project was supported by grant number 2R01AG039621 (to A.M.S.H.) and R01AG075583 (to A.M.S.H. and B.B.) from the National Institute on Aging. The content is solely the authors' responsibility and does not necessarily represent the official views of the National Institute on Aging or the National Institutes of Health. This project was supported by grant number 2R01AG039621 (to A.M.S.H.) and R01AG075583 (to A.M.S.H. and B.B.) from the National Institute on Aging . The content is solely the authors' responsibility and does not necessarily represent the official views of the National Institute on Aging or the National Institutes of Health.
| Financiadores | Número del financiador |
|---|---|
| National Institutes of Health (NIH) | |
| National Institute on Aging | R01AG075583 |
| National Institute on Aging |
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)
Huella
Profundice en los temas de investigación de 'Blood-brain barrier leakage in Alzheimer's disease: From discovery to clinical relevance'. En conjunto forman una huella única.Citar esto
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver